General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0RSBMJ
ADC Name
Sofituzumab vedotin
Synonyms
Anti-MUC16 monoclonal antibody MMAE; Anti-MUC16 monoclonal antibody monomethyl auristatin E conjugate; Anti-MUC16 monoclonal antibody vedotin; MMAE anti-MUC16; RG-7458; DMUC-5754A; MMAE anti-MUC16 mAb; Anti-MUC16 MMAE ADC; Anti-MUC16 mAb MMAE; Anti-MUC16 ADC MMAE; DMUC5754A
   Click to Show/Hide
Organization
Genentech, Inc.; Roche Holding AG
Drug Status
Terminated in phase 1
Indication
In total 4 Indication(s)
Fallopian tube cancer [ICD11:2C74]
Terminated in phase 1
Ovarian cancer [ICD11:2C73]
Terminated in phase 1
Pancreatic cancer [ICD11:2C10]
Terminated in phase 1
Peritoneal cancer [ICD11:2C51]
Terminated in phase 1
Drug-to-Antibody Ratio
3.5
Structure
Antibody Name
Anti-MUC16 Anti-ody 3A5
 Antibody Info 
Antigen Name
Mucin-16 (MUC16)
 Antigen Info 
Payload Name
Monomethyl auristatin E
 Payload Info 
Therapeutic Target
Microtubule (MT)
 Target Info 
Linker Name
Mc-Val-Cit-PABC
 Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
Vedotin
Puchem SID
472406306 , 223370458 , 312468222 , 384585219 , 404772778
Drugbank ID
DB15349
ChEBI ID
CHEMBL3545372

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.